Corgenix Medical Corp. and the ELITech Group Establish Strategic Alliance

Terms include initial US$1.25 million ELITech equity investment in Corgenix with options for US$3 million total, plus distribution agreement and diagnostic system co-development

DENVER and PARIS, July 19, 2010 - Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide
developer and marketer of diagnostic test kits, and the ELITech Group, a
Paris, France-based, privately held group of companies and worldwide
manufacturer and distributor of in-vitro diagnostic equipment and reagents,
today announced a broad strategic alliance. Terms of the agreement include:

    - Strategic Investment - ELITech will initially purchase 8,333,334 shares
      of Corgenix common shares at US$0.15 per share. ELITech is also
      committing to invest another US$750,000 in Corgenix common stock at
      the same price over the subsequent 12 months upon the successful
      completion by Corgenix of the two events specified below; warrants
      also issued at US$0.15 could potentially result in an additional
      US$1 million investment.
    - International Distribution - ELITech will become the master distributor
      for Corgenix outside of North America, significantly expanding global
      market coverage for Corgenix.
    - Product Development - Corgenix and ELITech will co-develop new tests by
      combining Corgenix products and technologies with several of the
      ELITech proprietary instrument systems.

"We are extremely pleased that the ELITech Group has chosen to establish
this relationship with Corgenix," said Douglass Simpson, Corgenix President
and Chief Executive Officer. "Investment in our company at a significant
premium to the current market price is evidence of ELITech's very strong
belief in Corgenix."

"This new collaboration confirms the vision and perspective of the
ELITech Group, which is driven by strategic partnerships with key players in
the in-vitro diagnostics (IVD) industry," said Pierre Debiais, the ELITech
Group's President. "The new relationship with Corgenix supports the Group's
commitment to the IVD market, demonstrates our strong desire to develop and
introduce new products, and significantly broadens our global position in
diagnostics."

"Adding Corgenix and the company's strength in immunology is a natural
expansion to ELITech's clinical chemistry and serology lines," continued
Pierre Debiais. "The partnership furthers ELITech's existing position in
unique microbiology products ranging from specific culture media and rapid
tests to multiplexing serology systems and infectious diseases molecular
diagnostics."

Philippe Veran, the ELITech Group's Financial Advisor, said the
transactions with Corgenix to continue ELITech's business expansion have been
made possible through the support of ELITech Group's core investors: NAXICAP
PARTNERS, SYNERGIE FINANCE, BNP PARIBAS DEVELOPPEMENT and IDIA DEVELOPPEMENT.

Further details of the transactions are included in an 8-K filing with
the U.S. Securities and Exchange Commission.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases and bone and
joint disorders, including the world's only non-blood-based test for aspirin
effect. Corgenix diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over 50
diagnostic products through a global distribution network. More information
is available at www.corgenix.com.

About the ELITech Group

The ELITech Group (ELITech) is a major player in the international
medical market. ELITech has brought together IVD specialty companies to
provide the best offering of innovative, unique and also routine products to
laboratories operating closer to the patient. It comprises Vital Scientific
and Seppim (clinical chemistry analyzers and reagents); ELITech Microbio
(microbiology kits); Wescor (unique laboratory instruments); inoDiag (unique
multiplex serology devices); Nanogen (leading edge technology molecular
biology kits); and SERFIB (microbiology and immunology kits). Through direct
sales in Europe and North America and distribution capabilities in over 100
countries, the ELITech Group offers clinical chemistry, microbiology,
immunology and molecular biology products from its own facilities as well as
complementary third-party products. More information is available at
www.elitechgroup.com

Statements in this press release that are not strictly historical facts
are "forward-looking" statements (identified by the words "believe",
"estimate", "project", "expect" or similar expressions) within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to,
continued acceptance of Corgenix's products and services in the marketplace,
competitive factors, changes in the regulatory environment, and other risks
detailed in Corgenix's periodic report filings with the Securities and
Exchange Commission. The statements in this press release are made as of
today, based upon information currently known to management, and Corgenix
does not undertake any obligation to publicly update or revise any
forward-looking statements.

Corporate and Financial, William Critchfield, Senior VP and CFO of Corgenix, +1-303-453-8903, wcritchfield at corgenix.com; or Media, Dan Snyders, Vice President and Public Relations Supervisor of Armada Medical Marketing, +1-303-623-1190, ext. 230, dan at armadamedical.com, for Corgenix; or Laetitia Crouch, Global Communications Manager of ELITech, +33(1)41-45-07-10, l.crouch at elitechgroup.com